Monte Rosa Therapeutics Inc
GLUE
NASDAQ
Biotechnology
$15.50
USD
-0.34 (-2.15%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $1.35B
Volume 509.2K
Revenue
$28.73M
TTM
-83.9%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-161.12M
TTM
-766.7%
YoY
Operating Cash Flow
$-24.07M
TTM
-186.8%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 23.2 | 12.8 | 2.8 | 4.2 | 9.0 |
YoY Growth | +394.0% | +38.5% | -95.4% | -95.0% | -61.3% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 23.2 | 12.8 | 2.8 | 4.2 | 9.0 |
Selling, General & Administrative | 8.1 | 9.1 | 10.5 | 10.2 | 10.1 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 38.7 | 45.7 | 52.5 | 54.2 | 58.1 |
Operating Income | -15.6 | -33.0 | -49.7 | -50.0 | -49.1 |
EBITDA | -13.4 | -30.9 | -47.6 | -48.0 | -47.2 |
Other Income / Expense | 1.4 | -0.0 | -0.1 | -0.0 | 0.0 |
Total Other Income / Expense | 4.5 | 2.7 | 3.6 | 5.6 | 5.9 |
Income Before Income Taxes | -11.1 | -30.3 | -46.1 | -44.5 | -43.2 |
Income Taxes | 1.2 | -3.2 | 0.1 | 0.1 | 0.2 |
Net Income | -12.3 | -27.1 | -46.1 | -44.5 | -43.4 |
Consolidated Net Income / Loss | -12.3 | -27.1 | -46.1 | -44.5 | -43.4 |
Net Income Attributable to Common Shareholders | -12.3 | -27.1 | -46.1 | -44.5 | -43.4 |
Basic EPS | -$0.15 | -$0.33 | -$0.54 | -$0.45 | -$0.43 |
Diluted EPS | -$0.15 | -$0.33 | -$0.54 | -$0.45 | -$0.43 |
Basic Shares Outstanding | 82.2M | 82.4M | 85.6M | 99.9M | 101.5M |
Diluted Shares Outstanding | 82.2M | 82.4M | 84.7M | 99.9M | 101.5M |